lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Trade names == Several companies have attempted to trademark particular strains, and as a marketing technique, have invented scientific-sounding names for the strains. Danone (Dannon in the United States) markets the subspecies strain DN 173 010 as Bifidus Digestivum (UK), Bifidus Regularis (US and Mexico), Bifidobacterium Lactis or B.L. Regularis (Canada), DanRegularis (Brazil), Bifidus Actiregularis (Argentina, Austria, Belgium, Bulgaria, Chile, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Kazakhstan, Netherlands, Portugal, Romania, Russia, South Africa, Spain and the UK), and Bifidus Essensis in the Middle East (and formerly in Hungary, Bulgaria, Romania and The Netherlands) through Activia from Safi Danone KSA. One notable example involved Danone’s attempt to enforce a trademark on an invented probiotic strain name. Danone held a trademark for “Bifidus Essensis”, which it used in marketing its Activia products, and sued Glanbia after the launch of Yoplait “Essence” products in the Irish market, claiming trademark infringement. In 2007, the Irish Commercial Court ruled against Danone, finding that the “Essensis” trademark had not been genuinely used as a product brand in the relevant market and ordering its revocation in that context. Chr. Hansen A/S from Denmark has a similar claim on a strain of Bifidobacterium animalis subsp. lactis, marketed under the trademark BB-12. Lidl lists "Bifidobacterium BB-12" in its "Proviact" yogurt. Bifidobacterium lactis Bl-04 and Bi-07 are strains from DuPont's Danisco FloraFIT range.
During the final stages of World War II in 1945, the United States conducted atomic raids on the Japanese cities of Hiroshima and Nagasaki, the first on August 6, 1945, and the second on August 9, 1945. These two events were the first and only times nuclear weapons have been used in combat. For six months before the atomic bombings, the U.S. 20th Air Force under General Curtis LeMay executed low-level incendiary raids against Japanese cities. The most destructive air raid to occur during the process was not the nuclear attacks, but the Operation Meetinghouse raid on Tokyo. On the night of March 9–10, 1945, Operation Meetinghouse commenced and 334 Boeing B-29 Superfortress bombers took off to raid, with 279 of them dropping 1,665 tons of incendiaries and explosives on Tokyo. The bombing was meant to burn wooden buildings and indeed the bombing caused fire that created a 50 m/s wind, which is comparable to tornadoes. Each bomber carried 6 tons of bombs. A total of 381,300 bombs, which amount to 1,783 tons of bombs, were used in the bombing. Within a few hours of the raid, it had killed an estimated 100,000 people and destroyed 41 km2 (16 sq mi) of the city and 267,000 buildings in a single night — the deadliest bombing raid in military aviation history other than the atomic raids on Hiroshima and Nagasaki. By early August 1945, an estimated 450,000 people had died as the U.S. had intensely firebombed a total of 67 Japanese cities. In late June 1945, as the U.S.
Hood's research group corrected the neurological defect in mice (the shiverer defect) by transferring a normal MBP gene into the fertilized egg of the shiverer mouse. These discoveries led to extensive studies of MBP and its biology.
The functional group of nitriles containing the C≡N triple bond is referred to as the nitrile or cyano group. If the nitrile is the highest-ranking functional group, the suffix -nitrile is added to the name of the parent compound. The triply bonded carbon atom is, as always, included in the parent chain. Alternatively, the ending -carbonitrile may be used (analogous to -carboxylic acid), in which case the carbon atom is not counted as part of the parent chain. This ending must be used if the nitrile group is attached to a ring (as in cyclopentanecarbonitrile) or if not all carbon atoms are part of the parent chain, which is necessarily the case when more than two nitrile groups are present, as these can only be located at the termini of the chain. Due to their relationship to carboxylic acids (the nitrile carbon has the same oxidation state as the carboxyl carbon), trivial names are often derived from the corresponding carboxylic acids using the ending -onitrile (for example, benzoic acid to benzonitrile). If the nitrile function is not the principal functional group in the molecule, the prefix cyano- is used together with the appropriate locant. In this case as well, the triple-bonded carbon atom is not counted as part of the parent chain.
=== Food preservative === In foods, TBHQ is used as an antioxidant preservative for unsaturated vegetable oils and many edible animal fats. It does not cause discoloration even in the presence of iron, and does not change flavor or odor of the material to which it is added. It can be combined with other preservatives such as butylated hydroxyanisole (BHA). As a food additive, its E number is E319. It is added to a wide range of foods. Its primary advantage is extending storage life.
Sources: en.wikipedia.org
A Clinical Data Repository (CDR) or Clinical Data Warehouse (CDW) is a real time database that consolidates data from a variety of clinical sources to present a unified view of a single patient. It is optimized to allow clinicians to retrieve data for a single patient rather than to identify a population of patients with common characteristics or to facilitate the management of a specific clinical department. Typical data types which are often found within a CDR include: clinical laboratory test results, patient demographics, pharmacy information, radiology reports and images, pathology reports, hospital admission, discharge and transfer dates, ICD-9 codes, discharge summaries, and progress notes. A Clinical Data Repository could be used in the hospital setting to track prescribing trends as well as for the monitoring of infectious diseases. One area CDR's could potentially be used is monitoring the prescribing of antibiotics in hospitals especially as the number of antibiotic-resistant bacteria is ever increasing. In 1995, a study at the Beth Israel Deaconess Medical Center conducted by the Harvard Medical School used a CDR to monitor vancomycin use and prescribing trends since vancomycin-resistant enterococci is a growing problem. They used the CDR to track the prescribing by linking the individual patient, medication, and the microbiology lab results which were all contained within the CDR.
Overlapping peptide libraries - in which the entirety of a larger protein is used to produce a library of 8-20 amino acid peptides which overlap; these libraries can be used to identify the specific regions of a larger protein which participate in a given interaction or to provide pre-digested versions of a larger protein for binding. Truncation peptide libraries - in which a given peptide is produced with various or all N or C terminal truncations, these smaller fragments can be used to identify the minimal required region of a peptide for a given interaction being studied. Random libraries - randomly generated peptides of a set length, or range of lengths, can be used to identify novel binding partners of a target of interest. Alanine scanning libraries - in which each amino acid of a given protein or peptide is replaced with an alanine sequentially such that each peptide contains only one alanine mutations but all possible mutations to alanine are present; this can be used to identify critical residues for binding Positional or scrambled peptide libraries - in which specific positions in the peptide are substituted for many or all other amino acids such that the effect of each amino acid at that position in the peptide on the binding or other activity of the peptide can be tested. Scrambled libraries are often random peptides and used as negative controls. Solid phase peptide synthesis is limited to a peptide chain length of approximately 70 amino acids and is generally unsuitable for the study of larger proteins.
== Clinical applications == Clinical application is extremely important to consider when looking at the efficacy of artificial cartilage. The recent clinical approaches for cartilage regeneration in Osteoarthritis treatment is described below.
Several reactions have been noted in manufacturer guidelines—deep sleep, incoordination, sedation, and dizziness have been reported in children and adults, as well as others such as hypotension, tinnitus, and headaches. Gastrointestinal effects have also been observed, as well as less serious effects such as dryness of the mouth and constipation caused by the mild antimuscarinic properties of hydroxyzine. Central nervous system effects such as hallucinations or confusion have been observed in rare cases, attributed mostly to overdosage. Such properties have been attributed to hydroxyzine in several cases, particularly in patients treated for neuropsychological disorders, as well as in cases where overdoses have been observed. While there are reports of hallucinogenic effects from use of hydroxyzine, several clinical data trials have not reported such side effects from the sole consumption of hydroxyzine, but rather, have described its overall calming effect through the stimulation of areas within the reticular formation. The hallucinogenic or hypnotic properties have been described as being an additional effect from overall central nervous system suppression by other CNS agents, such as lithium or ethanol. Hydroxyzine exhibits anxiolytic and sedative properties in many psychiatric patients. One study showed that patients reported very high levels of subjective sedation when first taking the drug, but that levels of reported sedation decreased markedly over 5–7 days, likely due to CNS receptor desensitization.
=== Functional and bioactive components === Among the functional proteins detected in donkey milk, there are molecules active in antimicrobial protection such as lysozyme and lactoferrin. The lactoferrin content of donkey milk is intermediate between the lower values of cow milk and the higher values of human milk. Lactoferrin inhibits the growth of iron-dependent bacteria in the gastrointestinal tract. This inhibits certain organisms, such as coliforms and yeast, that require iron. Lysozyme in donkey milk is present in large amounts, and ranges from 1.0 mg/mL to 4 mg/mL, depending on the analytical method used (chemical or microbiological); This substance is present also in humans (0.12 mg/mL) but only in trace amounts in cow and goat milk. Lysozyme in donkey milk is highly thermo-stable and is very resistant to acid and protease and may play a significant role in the intestinal immune response. In donkey mammary secretion, defatted or not, growth factors and hormones have also been determined. Donkey mammary secretions contain human-like leptin at levels close to human milk (3.35 e 5.32 ng/mL milk). The bioactive peptides insulin-like growth factor 1, ghrelin, and triiodothyronine were also found in frozen donkey milk. These molecules and many others present in human milk, are increasingly receiving attention from a nutraceutical point of view because of their potential direct role in regulating food intake, metabolism, and infant body condition.
Sources: en.wikipedia.org
2025: Datchinamurthy Kataiah, a Malaysian drug trafficker hanged for smuggling 44.96g of diamorphine on 25 September 2025. 2025: Pannir Selvam Pranthaman, a Malaysian drug trafficker hanged on 8 October 2025 for smuggling 51.84g of diamorphine. 2026: Omar Bin Yacob Bamadhaj, a Singaporean was hanged on 16 April 2026 for trafficking 1,009.1g of cannabis in July 2018
Though rare, estimates of the prevalence of vaginal cuff dehiscence after hysterectomy are estimated and reported to be between 0.14 and 4.1% per the American College of Obstetricians and Gynecologists (ACOG). If the vaginal cuff is compromised, vaginal evisceration can occur with the small intestine protruding out through the vagina.
==== JPT2 ==== The 20kDa Jupiter microtubule-associated homolog 2 (JPT2) (also known as HN1L) was the first accessory protein to be published as a mediator of NAADP-dependent Ca2+ release. Both studies exploited the same novel 'clickable' NAADP photoprobe, but regardless of the different blood cell types, the authors converged on the same molecular partner (although the studies differ in the channel that is activated). JPT2 binds [32P]NAADP with selectivity over a spectrum of different nucleotides. In Ca2+-release studies, NAADP-dependent signals were inhibited by siRNA knockdown of JPT2, but not of its homolog, JPT1, attesting to isoform specificity. Interestingly, JPT2 exhibited a preferential interaction with TPC1 over TPC2. Given that TPCs are known to drive pathogen uptake into cells, it was striking that uptake of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus was likewise reduced by JPT2 gene silencing.
The early or fulminant form of hemorrhagic smallpox (referred to as purpura variolosa) begins with a prodromal phase characterized by a high fever, severe headache, and abdominal pain. The skin becomes dusky and erythematous, and this is rapidly followed by the development of petechiae and bleeding in the skin, conjunctiva and mucous membranes. Death often occurs suddenly between the fifth and seventh days of illness, when only a few insignificant skin lesions are present. Some people survive a few days longer, during which time the skin detaches and fluid accumulates under it, rupturing at the slightest injury. People are usually conscious until death or shortly before. Autopsy reveals petechiae and bleeding in the spleen, kidney, serous membranes, skeletal muscles, pericardium, liver, gonads and bladder. Historically, this condition was frequently misdiagnosed, with the correct diagnosis made only at autopsy. This form is more likely to occur in pregnant women than in the general population (approximately 16% of cases in unvaccinated pregnant women were early hemorrhagic smallpox, versus roughly 1% in nonpregnant women and adult males). The case fatality rate of early hemorrhagic smallpox approaches 100%.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.